Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus

Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus

Author Grando, Aline Vitali Google Scholar
Abrao Ferreira, Paulo Roberto Autor UNIFESP Google Scholar
Pessoa, Mario Guimaraes Google Scholar
de Campos Mazo, Daniel Ferraz Google Scholar
Brandao-Mello, Carlos Eduardo Google Scholar
Reuter, Tania Google Scholar
Candolo Martinelli, Ana de Lourdes Google Scholar
Gonzalez, Mario Peribanez Google Scholar
Seixas-Santos Nastri, Ana Catharina Google Scholar
Campos, Aleia Faustina Google Scholar
Banks Ferreira Lopes, Max Igor Google Scholar
Urbaez Brito, Jose David Google Scholar
Mendes-Correa, Maria Cassia Google Scholar
Abstract Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers. The study sample included 184 GEN3/CHC patients

70 (38%) were co-infected with HIV. The overall SVR rate was 57.1% (95% CI 50-64). Among co-infected and mono-infected patients, the SVR rate was 51.4% (36/70) and 60.5% (69/114), respectively (p=0.241). Thirty-four (18.5%) patients experienced SAE and interrupted treatment. SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75

95% CI 0.58-0.99

p=0.045) and to early treatment interruption due to SAE (PR 0.36

95% CI 0.20-0.68

p=0.001). Early treatment interruption due to SAE was associated with age (PR 1.06

95% CI 1.02-1.10

p<0.001) and occurrence of liver cirrhosis (PR 2.06

95% CI 1.11-3.83

p=0.022). In conclusion, Peg-IFN/RBV might represent an adequate treatment option, mainly in young patients without advanced liver disease or when the use of direct-action drugs is limited to specific patient groups.
Keywords Hepatitis C
Chronic hepatitis C
Coinfection HCV-HIV
Interferons
Ribavirin
HCV genotypes
xmlui.dri2xhtml.METS-1.0.item-coverage Sao Paulo
Language English
Date 2017
Published in Revista Do Instituto De Medicina Tropical De Sao Paulo. Sao Paulo, v. 59, p. -, 2017.
ISSN 0036-4665 (Sherpa/Romeo, impact factor)
Publisher Inst Medicina Tropical Sao Paulo
Extent -
Origin http://dx.doi.org/10.1590/S1678-9946201759067
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000414712400001
SciELO ID S0036-46652017005000239 (statistics in SciELO)
URI https://repositorio.unifesp.br/handle/11600/55442

Show full item record




File

Name: S0036-46652017005000239.pdf
Size: 315.2Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account